QualityStocksNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Completion of Patient Enrollment for Study of Cannabidiol Lotion for Eczema Treatment
Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has completed patient enrollment in its upcoming clinical study of JW-100, its proprietary cannabidiol lotion formulation for the treatment of atopic dermatitis, or eczema. The study is designed to investigate the efficacy and safety of JW-100. JUPW enrolled 66 patients for the multi-center, double-blinded, placebo-controlled trial. Study participants will be randomly selected to receive one of three topical formulations, including a placebo, at least twice daily. Data from the study is expected in Q1 2021. "We are eager to see the results of this trial,…